drugset / Trial / NCT01441960

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

NCT01441960

Completed 45 enrolled Massachusetts General Hospital
RandomizedCrossoverDouble-blindTreatment

Summary

Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to the brain to produce generalized seizures for the treatment of selected psychiatric disorders such as severe depression. The aim of ECT is to induce a therapeutic tonic seizure where the person loses consciousness and has convulsions. Patients need general anesthesia and neuromuscular blockade to treat pain and avoid excessive tonic clonic motor contraction that might be associated with compression fractures. Neuromuscular blocking drugs (NMBD) are, therefore, administered after induction of general anesthesia to induce neuromuscular blockade. Despite the importance of NMBDs to provide optimal conditions for ECT treatment, the optimal NMBD dose to achieve acceptable neuromuscular blockade without excessive or untoward effects has not previously been identified in any study and in a prospective randomized fashion. The aim of this study is, therefore, to identify the optimal NMBD dose of two commonly used neuromuscular blocking agents (succinylcholine and rocuronium) in order to optimize the muscle strength modulation during ECT that facilitates ECT with the minimal side effects.

Timeline

Start
2011-05
Primary completion
2013-07
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocuronium Other / unclassified
Subject Suxamethonium Other / unclassified

Indications

No indication recorded.